| 引用本文： |
-
施嫣红,汤茂春,虞卫华,等.美沙拉嗪治疗轻中度溃疡性结肠炎的临床疗效研究[J].同济大学学报（医学版）,2015,36(6):103-107. [点击复制]
- SHI Yan-hong,TANG Mao-chun,YU Wei-hua,et al.Clinical effect of the treatment of mild to moderate ulcerative colitis with the United States of America[J].同济大学学报（医学版）,2015,36(6):103-107. [点击复制]
|
|
| 摘要: |
| 目的 观察利福昔明胶囊联合美沙拉嗪片治疗轻中度溃疡性结肠炎患者的临床疗效。方法 90例轻度、中度溃疡性结肠炎病人随机分为观察组46例、对照组44例。观察组给予美沙拉嗪片1.0g,每日4次,利福昔明胶囊0.2g,每日4次。对照组单用美沙拉嗪片1.0g,每日4次。总疗程为8周,观察两组治疗前后的临床活动指数、内镜评分、病理评分、临床综合疗效及不良反应。结果 治疗8周后,两组患者的临床活动指数均较治疗前显著降低(5.48±2.33比2.59±1.78,5.59±1.98比3.73±2.20,P＜0.05),且观察组的临床活动指数显著低于对照组(P＜0.05)；两组患者治疗后的内镜评分、病理评分显著低于治疗前(P<0.01),观察组比对照组能更有效地改善患者的内镜评分及病理评分(P<0.01)；观察组总有效率87.0%,显著高于对照组的68.2%(χ2=4.141,P<0.05)。两组不良反应发生率无显著差异(P>0.05)。结论 美沙拉嗪片联合利福昔明胶囊治疗轻中度UC可有效改善患者的临床活动指数、内镜下及病理评分,且副反应少。 |
| 关键词: 溃疡性结肠炎 美沙拉嗪 利福昔明 疗效 |
| DOI：10.16118/j.1008-0392.2015.06.021 |
| 投稿时间：2015-05-25 |
| 基金项目: |
|
| Clinical effect of the treatment of mild to moderate ulcerative colitis with the United States of America |
| SHI Yan-hong,TANG Mao-chun,YU Wei-hua,WENG Yun,WANG Jun-shan,LIU Zhan-jiu |
| (Dept. of Gastroenterology, Tenth People's Hospital, Tongji University, Shanghai 200072, China) |
| Abstract: |
| Objective To evaluate the therapeutic effects of sulfasalazine combined with rifaximin in treatment of patients with mild or moderate ulcerative colitis (UC). Methods Ninety patients with mild or moderate UC were divided into two groups randomly: 44 patients received sulfasalazine 1.0g p.o. q.i.d alone for 8 weeks (control group) and 46 patients also received rifaximin 0.2g p.o. q.i.d for 8 weeks in addition to sulfasalazine (study group). The effective rate, modified Mayo scores, endoscopic index of severity (UCEIS), histopathological scores and adverse reactions of patients were analyzed and compared between two groups. Result After 8-week treatment, Mayo scores of both groups were lower than those before treatment (5.48±2.33 vs 2.59±1.78,5.59±1.98 vs 3.73±2.20, respectively, both P＜0.05). Mayo scores in study group decreased more significantly than that in control group (P＜0.05). After 8 weeks, UCEIS and histopathological scores of two groups were statistically decreased than those before treatment (P＜0.01). The UCEIS and histopathological scores were more markedly improved in study group than those in control group (P＜0.01). The effective rate of study group was 87%, which was higher than that of control group (68.2%, P＜0.05). There was no significant difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion Sulfasalazine combined with rifaximin can effectively improve the clinical efficacy of patients with mild or moderate ulcerative colitis. |
| Key words: ulcerative colitis sulfasalazine Rifaximin efficacy |
